Transaction details
Serge Saxonov, the Chief Executive Officer of 10x Genomics (NASDAQ: TXG), sold 5,000 shares of the company’s Class A common stock on April 14, 2026. The shares were transacted at prices between $24.49 and $24.70, producing gross proceeds of $122,784. The disposition was carried out under a Rule 10b5-1 trading plan that Saxonov adopted on November 29, 2025.
Post-sale holdings
After the sale, Saxonov’s direct ownership in 10x Genomics stands at 1,167,273 shares. He also has indirect stakes that include 27 shares held by the Andromeda Trust, 213,250 shares held by the Y/S Descendants’ Trust, and 71,644 shares held by the Y/S Pot Trust, for which he serves as trustee.
Market context
The share sale happened while the stock was trading close to its 52-week high of $25.69. Over the past year, 10x Genomics’ shares have appreciated roughly 216 percent. Separately, analysis from InvestingPro flags the stock as appearing overvalued at current levels.
Analyst and institutional activity
Market participants and analysts have recently shown a range of views on 10x Genomics. William Blair upgraded the company to an Outperform rating, citing its role in AI-driven drug discovery and pointing to operational momentum - five consecutive top-line beats and adjusted EBITDA reaching breakeven, alongside fourth consecutive quarters of double-digit single-cell volume growth.
Stifel raised its price target to $25 and kept a Buy rating, referencing steady adoption of the company’s new Flex Apex product.
At the same time, Wolfe Research noted a sell-off in spatialomics stocks, including 10x Genomics, tied to concerns that advances in AI could reduce demand for spatial proteomics. Institutional activity has been notable as well: ARK Invest sold slightly more than 473,000 shares of 10x Genomics, a move that contributes to questions about institutional conviction in companies that supply genomics research tools.
Strategic partnerships and scale initiatives
On the partnership front, Bioptimus launched the Spatial Tissue Embedding Learning Atlas (STELA) in collaboration with 10x Genomics and Broad Clinical Labs. The initiative aims to profile up to 100,000 patient tissue specimens globally, representing a material increase in scale compared with existing spatial biology atlases.
What this means
The disclosed insider sale was executed under a standing trading plan and represents a modest cashing-out relative to Saxonov’s total direct and indirect holdings. It coincides with a period of strong share-price performance and a mix of positive operational updates, analyst upgrades, and institutional selling. Investors looking to reconcile the company's recent execution metrics against valuation concerns face a set of mixed signals: improving operational indicators and strategic partnerships on one hand, and questions around valuation and sector-specific demand drivers on the other.